Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Bone. 2018 May 16;113:77–88. doi: 10.1016/j.bone.2018.05.008

Figure 3. Early TGF-β inhibition alters mature myeloid expression at middle disease for tumor-bearing TGF-βRIIMyeKO mice.

Figure 3

Bone marrow was harvested and prepared for flow cytometry as described in the methods section. A. No significant expansion differences in monocytic immature myeloid cells (CD11b+ CD11c− Ly6G− Ly6C+)) between tumor-bearing WT and TGF-βRIIMyeKO mice. B. No significant expansion differences in granulocytic immature myeloid cells (CD11b+ CD11c− Ly6C− Ly6G+) between tumor-bearing WT and TGF-βRIIMyeKO mice. C. Mature myeloid cells (CD11b+ F4/80+) from tumor-bearing TGF-βRIIMyeKO mice increase in cell percentage at middle disease. (5-6 mice per group).